Agios Pharmaceuticals, Inc. AGIO announced that the FDA has granted orphan drug designation to its novel pyruvate kinase (PK) activator, tebapivat, for the treatment of myelodysplastic syndromes ...

The following is a summary of “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations ...

Artificial photosynthesis technology was developed with the addition of the biocatalyst L-alanine dehydrogenase, which combines ammonia with pyruvate to produce L-alanine, to the photoredox system ...

The inducement grants consisted of (i) a nonstatutory option to purchase up to 55,374 shares of common stock, (ii) restricted stock units for 24,300 shares of common stock and (iii) performance stock ...

This stage does not require oxygen. If oxygen is available to the cell then the pyruvate molecules can be further broken down in stage two to release more energy and produce a greater quantity of ATP.

Cancer cells are known to favor aerobic glycolysis for energy production, a phenomenon termed the Warburg effect.

PDHX acetylation promotes tumor progression by disrupting PDC assembly and activating lactylation-mediated gene expression.